Literature DB >> 18044766

Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation.

Takashi Ito1, Yasutsugu Takada, Mikiko Ueda, Hironori Haga, Yoji Maetani, Fumitaka Oike, Kohei Ogawa, Seisuke Sakamoto, Yasuhiro Ogura, Hiroto Egawa, Koichi Tanaka, Shinji Uemoto.   

Abstract

In the present study, the results of living donor liver transplantation (LDLT) for 125 hepatocellular carcinoma (HCC) patients were analyzed to determine optimal criteria exceeding the Milan criteria (MC) but still with predictably good outcomes. On the basis of pretransplant imaging studies, 70 patients met the MC, and 55 patients did not. Patients who exceeded the MC but presented with <or=10 tumors all<or=5 cm in diameter (n=30) displayed 5-year recurrence rates (7.3%) similar to those of patients within the MC (9.7%, P=0.8787). According to the results of multivariate analysis of risk factors for recurrence among preoperative tumor variables, we have defined the new criteria, namely <or=10 tumors all<or=5 cm in diameter and protein induced by vitamin K absence or antagonist-II (PIVKA-II)<or=400 mAU/mL. The 78 patients who met the new criteria showed significantly lower 5-year recurrence rates (4.9%) than the 40 patients who exceeded them (60.5%, P<0.0001). Similarly, 5-year survival rates significantly differed between these groups (86.7% versus 34.4%, respectively; P<0.0001). In conclusion, selection criteria for patients with HCC undergoing LDLT may be safely extended to <or=10 tumors all<or=5 cm in diameter and PIVKA-II<or=400 mAU/mL with acceptable outcomes. Copyright (c) 2007 AASLD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18044766     DOI: 10.1002/lt.21281

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  71 in total

Review 1.  Surgical management of hepatocellular carcinoma.

Authors:  Tony Cy Pang; Vincent Wt Lam
Journal:  World J Hepatol       Date:  2015-02-27

2.  Living donor liver transplantation for hepatocellular carcinoma: is surgeon a prognostic factor?

Authors:  Rajeev Sharma
Journal:  Indian J Gastroenterol       Date:  2009 Mar-Apr

3.  Optimal treatment for hepatocellular carcinoma in the cirrhotic liver.

Authors:  S A White; D M Manas; S G Farid; K R Prasad
Journal:  Ann R Coll Surg Engl       Date:  2009-10       Impact factor: 1.891

4.  Living-donor or deceased-donor liver transplantation for hepatic carcinoma: a case-matched comparison.

Authors:  Ping Wan; Jian-Jun Zhang; Qi-Gen Li; Ning Xu; Ming Zhang; Xiao-Song Chen; Long-Zhi Han; Qiang Xia
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 5.  Liver transplantation for hepatocellular carcinoma.

Authors:  See Ching Chan
Journal:  Liver Cancer       Date:  2013-08       Impact factor: 11.740

6.  Significance of platelet count in the outcomes of hepatectomized patients with hepatocellular carcinoma exceeding the Milan criteria.

Authors:  Hironobu Amano; Hirotaka Tashiro; Akihiko Oshita; Tsuyoshi Kobayashi; Yoshisato Tanimoto; Shintaro Kuroda; Hirofumi Tazawa; Toshiyuki Itamoto; Toshimasa Asahara; Hideki Ohdan
Journal:  J Gastrointest Surg       Date:  2011-04-22       Impact factor: 3.452

Review 7.  Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation.

Authors:  Marta Guerrero-Misas; Manuel Rodríguez-Perálvarez; Manuel De la Mata
Journal:  World J Hepatol       Date:  2015-04-08

8.  What liver surgeons have achieved in the recent decade for patients with hepatocellular carcinoma?

Authors:  Takashi Kokudo; Norihiro Kokudo
Journal:  Glob Health Med       Date:  2020-10-31

9.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

10.  FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma.

Authors:  Tatsuya Higashi; Etsuro Hatano; Iwao Ikai; Ryuichi Nishii; Yuji Nakamoto; Koichi Ishizu; Tsuyoshi Suga; Hidekazu Kawashima; Kaori Togashi; Satoru Seo; Koji Kitamura; Yasutsugu Takada; Yasuji Takada; Shinji Uemoto; Shinji Kamimoto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-17       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.